February 25th 2020
Caitlin Costello, MD, discusses pivotal research in the relapsed/refractory multiple myeloma setting.
February 24th 2020
Erin Reid, MD, discusses the treatment advances across lymphomas and the remaining questions that need to be answered with further research.
Sumanta K. Pal, MD, discusses the cohort 6 findings of the COSMIC-021 trial and other key data that were presented during the 2020 Genitourinary Cancers Symposium.
February 21st 2020
Benjamin J. Miller, MD, MS, discusses the creation of the Musculoskeletal Tumor Registry and how it is poised to make progress in the orthopedic oncology field.
February 20th 2020
Sara A. Hurvitz, MD, Neelima Denduluri, MD, and Madelaine Kuiper, MSN, RN, discuss the rise of HER2-targeted therapies and their implications on the field.
February 19th 2020
Ruth O’Regan, MD, shares her perspective on the use of biosimilars in breast cancer and their future in oncology.
Anne Chiang, MD, PhD, discusses the currently available treatments and ongoing research in ALK-positive non–small cell lung cancer.
February 18th 2020
Julia Fehniger, MD, discusses emerging strategies in the treatment paradigm for patients with BRCA1/2-mutant endometrial cancer.
February 15th 2020
Jasmeet C. Singh, MD, discusses the findings of a retrospective analysis and how they may impact treatment for patients with HER2-positive breast cancer.
February 10th 2020
Julie R. Brahmer, MD, discusses the impact of osimertinib in EGFR-mutant non–small cell lung cancer, ongoing research with the agent, and the importance of molecular testing.
Shebli Atrash, MD, discusses some of the latest intriguing research in relapsed/refractory multiple myeloma.
Significant research advances in targeted therapy and immunotherapy within the past years have created a more personalized approach to treatment for patients with advanced non–small cell lung cancer.
February 8th 2020
Benjamin P. Levy, MD, discusses emerging oncogenic markers in lung cancer and what impact they are poised to make on the paradigm.
February 5th 2020
Adam M. Brufsky, MD, PhD, FACP, discusses the emergence of biosimilars in oncology and how he anticipates they will change the paradigm.
Roy S. Herbst, MD, PhD, discusses research regarding immunotherapy and accompanying biomarkers in non–small cell lung cancer.
February 4th 2020
Melissa K. Accordino, MD, MS, discusses the treatment options for patients with hormone receptor-positive, HER2-negative breast cancer.
James M. Reuben, PhD, MBA, discusses his research on using liquid biopsies to identify predictive biomarkers for immunotherapy in patients with metastatic breast cancer.
January 30th 2020
Thomas J. Scharschmidt, MD, MBOE, discusses the use of targeted muscle reinnervation for amputee patients with cancer as well as therapeutic advances in sarcoma and tenosynovial giant cell tumor.
January 29th 2020
C. Parker Gibbs, MD, discusses the research behind p16 and p21 as predictive biomarkers for treatment response in patients with osteosarcoma.
A. Oliver Sartor, MD, discusses the development of radiopharmaceuticals in prostate cancer.